Merkel细胞癌单中心治疗及转归  

Treatment and Outcome of Merkel Cell Carcinoma in A Single Center

作　　者：任梦薇 薛学敏 刘鹏 REN Mengwei;XUE Xuemin;LIU Peng(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital,Chinese Academy of Medical Sciences,Langfang 065001,China;Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100000,China;Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100000,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/河北中国医学科学院肿瘤医院内科,廊坊065001 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科,北京100000 [3]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院病理科,北京100000

出　　处：《肿瘤防治研究》2023年第4期364-369,共6页Cancer Research on Prevention and Treatment

摘　　要：目的探讨Merkel细胞癌患者的临床特征、治疗方法及转归特点。方法回顾性分析2017年以来中国医学科学院肿瘤医院收治的6例Merkel细胞癌患者的临床表现、辅助检查、诊治经过及随访资料。结果6例Merkel细胞癌患者中男4例、女2例,中位发病年龄66岁(57~76岁)。6例患者均以出现皮肤肿物起病,临床分期:Ⅰ期3例、Ⅲ期1例、Ⅳ期2例。单纯手术治疗2例、手术联合放疗和(或)化疗3例,免疫治疗联合化疗1例。截至随访时间,4例疾病无进展,1例因疾病进展死亡,1例仍规律治疗中。结论局限期Merkel细胞癌以手术、放疗为主,转移性Merkel细胞癌多需应用全身治疗,一线选择靶向程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)途径的免疫检查点抑制剂可取得较好的治疗效果。Objective To investigate the clinical features,treatment,and outcome characteristics of patients with Merkel cell carcinoma.Methods The clinical manifestations,laboratory tests,diagnosis and treatment,and follow-up data of six patients with Merkel cell carcinoma were retrospectively analyzed.Results Among the six patients with Merkel cell carcinoma,four were males and two were females,with a median age of 66 years old(57-76 years old).All six patients presented with skin swelling,and the clinical stages were as follows:stageⅠin three patients,stageⅢin one patient,and stage IV in two patients.Two patients were treated with surgery alone,three patients with surgery combined with radiotherapy and/or chemotherapy,and one patient with immunotherapy combined with chemotherapy.Until the follow-up time,four patients had no disease progression,one patient died because of disease progression,and one patient remained under treatment.Conclusion Limited-stage Merkel cell carcinoma is primarily treated with surgery and radiotherapy,meanwhile,metastatic Merkel cell carcinoma needs systemic therapy,and first-line immune checkpoint inhibitors targeting PD-1/PD-L1 pathway can achieve better therapeutic results.

关 键 词：MERKEL细胞癌 皮肤神经内分泌癌 手术治疗 放疗 化疗 免疫检查点抑制剂 

分 类 号：R739.5[医药卫生—肿瘤]